Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $20.93, but opened at $19.84. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $20.32, with a volume of 40,699 shares changing hands.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on TLX. UBS Group upped their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.
View Our Latest Stock Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Performance
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- 3 Tickers Leading a Meme Stock Revival
- Home Depot Turns a Corner: New Highs Likely This Year
- How is Compound Interest Calculated?
- February’s Top 3 Stock Upgrades: What Investors Need to Know
- Why Are These Companies Considered Blue Chips?
- 2 Safe-Haven Stocks Shielded From Import Tariffs
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.